TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04571385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to AP30663.
Study: NCT03079973
Drug: P-3073 (calcipotriene 0.005%)
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
Study: NCT03079973
Drug: Vehicle of P-3073
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 24 weeks.
Study: NCT02119806
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
Study: NCT02087943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally twice a day (BID)
Study: NCT02493530
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established.
Study: NCT01129375
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Study: NCT02074800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single-dose of matching placebo intravenously in Part 1.
Study: NCT00983541
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
Study: NCT00590538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is given to match the active comparator for four days.
Study: NCT02109406
Drug: AZD2115 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD 2115, Dose 1 administered as two inhalations BID
Study: NCT02109406
Drug: AZD 2115, Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD 2115, Dose 2 administered as two inhalations BID
Study: NCT02109406
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI administered as two inhalations BID
Study: NCT02944435
Drug: CB-839 Capsules
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 200 mg CB-839 Capsules (Reference Formulation)
Study: NCT02944435
Drug: CB-839 Tablets
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 200 mg CB-839 Tablets (Test Formulation)
Study: NCT01118572
Drug: etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01118572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01303614
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
Study: NCT00703118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
Study: NCT04046822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study: NCT01608516
Drug: 68Ga-NODAGA-RGD PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
Study: NCT03167255
Drug: NS-065/NCNP-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received during weekly intravenous infusions
Study: NCT01162889
Drug: ATR-107 (PF-05230900) SC Injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single intravenous infusion, 60 minute duration
Study: NCT02452255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months
Study: NCT00814541
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01162889
Drug: ATR-107 (PF-05230900) SC Injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single subcutaneous injection
Study: NCT01162889
Drug: ATR-107 (PF-05230900) IV Infusion
Normalized name: SET,INFUSION MINIMED #MMT-107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion, 60 minute duration
Study: NCT00520052
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
Study: NCT03013985
Drug: Glulisine Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
Study: NCT03738761
Drug: Amlessa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
Study: NCT03738761
Drug: Co-Amlessa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
Study: NCT00099177
Drug: ibandronate [Bondronat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg iv on days 1-3, and 50mg po from day 22 to week 24
Study: NCT00099177
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg iv on day 1, and every 3-4 weeks
Study: NCT03681184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by SC injection
Study: NCT03174288
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of spironolactone
Study: NCT00103298
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02156063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02682511
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with oral ifetroban or placebo daily for 365 days
Study: NCT00196430
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04517045
Drug: Dachengqi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
Study: NCT04517045
Drug: probiotic L9
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: L92 2 tablets/time, tid, oral or nasal feeding
Study: NCT01380691
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01380691
Drug: Placebo-matching LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01380691
Drug: Placebo-matching alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01380691
Drug: Alcoholic beverage
Normalized name: Alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00006110
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenous infusion every 3 weeks for four cycles
Study: NCT00006110
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
Study: NCT01516645
Drug: KHK2898
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT02897063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT03609190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of NaCl over 40 min
Study: NCT01368887
Drug: Nicotinamide Monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study: NCT00553293
Drug: recombinant follicle stimulating hormone (Gonal-f)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFSH 150 iu/day
Study: NCT03994484
Drug: HA121-28 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study: NCT03994484
Drug: HA121-28 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study: NCT02182154
Drug: BIBF 1120 ES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00893971
Drug: PT001 + PT005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PT001 + PT005, single dose
Study: NCT02300623
Drug: Antiretroviral therapy alone
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiretroviral therapy
Study: NCT03530319
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Study: NCT03530319
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Study: NCT03813641
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
Study: NCT02314312
Drug: Everolimus + low dose cyclosporin A + prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02314312
Drug: Standard immunosupressive regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02927496
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Study: NCT02927496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
Study: NCT02855177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as suspension administered every 8 hours, with food
Study: NCT02372344
Drug: AZD0585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
Study: NCT02179749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, Four tablets daily/am for 1-week duration.
Study: NCT04039321
Drug: ESPB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
Study: NCT04039321
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
Study: NCT01538849
Drug: YH4808 A mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet = YH4808 A mg
Study: NCT01538849
Drug: YH4808 B mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet = YH4808 B mg
Study: NCT02997605
Drug: GlucoCorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone.
Study: NCT01059773
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
Study: NCT00463840
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00636636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily; 300 mg and 600 mg tablets
Study: NCT00494221
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00494221
Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01366638
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule taken by mouth once daily for 12 weeks
Study: NCT00000213
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03934359
Drug: DN1508052-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
Study: NCT00477204
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20 mg daily
Study: NCT00477204
Drug: Ezetimibe/Simvastatin
Normalized name: EZETIMIBE/SIMVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10mg)/Simvastatin (20mg)
Study: NCT04484844
Drug: TOKUYAMA SHIELD FORCE PLUS
Normalized name: Peroxy Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reinforcing (SR) monomer technology
Study: NCT01803087
Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03796676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03796676
Drug: PF04965842
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg QD
Study: NCT01085084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study: NCT01733992
Drug: R348 Ophthalmic Solution, 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
Study: NCT01733992
Drug: R348 Ophthalmic Solution, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
Study: NCT01733992
Drug: R348 Ophthalmic Solution, 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
Study: NCT01733992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, single and multiple ascending dose
Study: NCT02724566
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
Study: NCT04525326
Drug: mFOLFOX/FOLFIRI ( Standard Chemotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Chemotherapy
Study: NCT02389374
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose
Study: NCT00726258
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological serum
Study: NCT01204775
Drug: Placebo (Saxagliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once daily, 1-16 weeks
Study: NCT02192853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 4: placebo tablet
Study: NCT02913105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard Gelatin Capsule
Study: NCT01172808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that represents comparator
Study: NCT01172808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that represents BI drug
Study: NCT01937715
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
Study: NCT01937715
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose FOLFIRI regimen every 2 weeks
Study: NCT03671785
Drug: PRIM-DJ2727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
Study: NCT03671785
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
Study: NCT02295332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo capsules to RG7625, according to treatment schedule
Study: NCT02295332
Drug: RG7625
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, capsules, single ascending dose according to treatment schedule
Study: NCT00198523
Drug: Prednisolone and Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00198523
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02815267
Drug: FMX-101, 4% minocycline foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
Study: NCT03074968
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline application
Study: NCT02374437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Study: NCT02290145
Drug: TPF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day
Study: NCT02128334
Drug: Eligard 45 mg Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: NCT03099226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo blue hard gelatine capsules
Study: NCT03099226
Drug: BIA 5-453
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
Study: NCT02143934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pills, appearance identical to Primaquine tablets
Study: NCT02143934
Drug: Artemether Lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01648998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00359294
Drug: PM00104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously over 1 hour daily for 5 days, every 3 weeks.